Cellulite News and Research

RSS

Cellulite describes a condition that is claimed to occur in most women, where the skin of the lower limbs, abdomen, and pelvic region becomes dimpled.

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.

9 Oct 2014

Cynosure's PicoSure Picosecond Laser Workstation receives FDA clearance for treatment of wrinkles

Cynosure, Inc., a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that it has received FDA 510(k) clearance to market its flagship PicoSure Picosecond Laser Workstation for the treatment of wrinkles with the Company's new disposable energy delivery system, the FOCUS lens array.

24 Sep 2014

New Jersey physician offers FDA-approved non-invasive fat reduction treatment

Arthur W. Perry, MD, FACS, a New Jersey based board-certified plastic surgeon, is the first physician in the Central New Jersey region to offer UltraShape™, a revolutionary treatment recently FDA cleared for Fat Cell Destruction.

23 Sep 2014

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

21 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.

7 Aug 2014

Syneron Medical to host investor meeting to highlight opportunities in body contouring/fat treatment market

Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.

26 Jul 2014

Cynosure gets marketing approval from FDA for PicoSure Picosecond Laser Workstation

Cynosure, Inc., a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that it has received FDA 510(k) clearance to market its flagship PicoSure Picosecond Laser Workstation for the treatment of acne scars with the FOCUS lens array, the Company's new disposable energy delivery system.

24 Jul 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

Auxilium Pharmaceuticals presents new XIAFLEX clinical trial data at AUA Meeting

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD).

19 May 2014

Syneron Candela looks at latest non-invasive body shaping technologies

Join Syneron Candela for an extraordinary look at the latest non-invasive body shaping technologies on May 31, 2014 with renowned plastic surgeon Stephen Mulholland, MD.

12 May 2014

Chromogenex launches non-surgical fat reduction and body shaping system

Chromogenex, a world leader in laser innovation, announced today the launch of i-LipoXcell, the company's non-surgical fat reduction and body shaping system. Representing third generation technology, i-LipoXcell incorporates both visible red and infrared lasers for bio-stimulation of metabolic pathways, effectively shrinking fat cells through the release of fatty acids and glycerol.

7 Apr 2014

Syneron's Sublative technology receives CE Mark for effective treatment of striae, acne scars

Syneron Medical Ltd., a leading global aesthetic device company, announced today that its proprietary Sublative™ technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars.

3 Apr 2014

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

Syneron Medical enters into agreement to acquire New Star Lasers

Syneron Medical Ltd., the leading global aesthetic device company, announced today that it has entered into an agreement to acquire New Star Lasers, Inc., which conducts business as CoolTouch, Inc., for approximately $11 million in cash and earn out based on certain milestones of up to $4 million until end of 2015.

20 Feb 2014

Auxilium Pharmaceuticals reports interim data from XIAFLEX Phase 4 study in patients with DC

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord will be presented for the first time at the American Association for Hand Surgery 2014 Annual Meeting being held January 8-11, 2014 in Kauai, Hawaii.

9 Jan 2014

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum for the treatment of frozen shoulder syndrome (adhesive capsulitis).

16 Dec 2013